Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations
Nucleic Acids Research · 23.09.2025 · 53 (18)
DOI: 10.1093/nar/gkaf778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 29.09.2025. Verfasst von Jesper Kammersgaard Christensen und 37 weiteren Autor:innen. Beteiligte Einrichtung: Development ADME, Novo Nordisk, Novo Nordisk Park, Måløv 2760, Denmark. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, RNA, Small Interfering, Translational Research, Biomedical. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IQ companies.
Abstract (Originalsprache)
RNA-based therapies, particularly small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), represent a promising modality class with the potential to target previously “undruggable” proteins, and with potential for precision medicine approach. The successful development of these therapeutics relies on a comprehensive understanding of several key factors, including bioconjugation, bioanalytical techniques, biotransformation, tissue distribution, computational modeling and simulation, and clinical pharmacology. Bioconjugation strategies are essential for enhancing metabolic stability, facilitating cellular uptake, and targeting specific tissues, thereby improving efficacy and minimizing dosing. Tailored bioanalytical methods are crucial for assessing pharmacokinetics (PK) and pharmacodynamics, with particular emphasis on tissue PK in cases where plasma PK does not reflect therapeutic activity. Biotransformation and tissue distribution studies are essential, although a less comprehensive package may be adequate for well-established chemistry. Given the unique properties of oligonucleotides, computational modeling plays a critical role in predicting drug behavior in target tissues, supporting dose optimization. Clinical pharmacology for oligonucleotides is less complex than for small molecules, as they are less likely to interact with common drug metabolizing enzymes or transporter proteins. This white paper, developed by the Innovation and Quality (IQ) Consortium Nucleic Acids Working Group, consolidates industry insights and recommendations to inform best practices and regulatory guidelines, ensuring the safe and efficient development of siRNA and ASO therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Development ADME, Novo Nordisk, Novo Nordisk Park, Måløv 2760, Denmark.
- Precision Medicine, BioAnalytical & Translational Sciences, Bristol Myers Squibb, Princeton, NJ 08543, United States.
- Investigative ADME/Toxicology and Bioanalytical Research, Eli Lilly and Company, Indianapolis, IN 46285, United States.
- Drug Metabolism and Pharmacokinetics, Eisai Inc., Cambridge, MA 02140, United States.
- DMPK&M, Takeda Pharmaceutical, Cambridge, MA 02142, United States.
- Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, 431 53 Gothenburg, Sweden.
ORCID-Profile: Sara Humphreys, Vibha Jawa
Förderung
- IQ companies
Zitieren
APA
Christensen, J. K., Colletti, N., Hooshfar, S., Jiang, R. R., Kuo, C., Lindmark, B., Lumen, A., Youssef, A. S., Albertolle, M., Aluri, K. C., Chen, L., Chen, J., Chopda, G., Chua, X. Y., Morais, P., Dubois, B., Gibbons, F. F., Gudey, S. K., Gupta, S., …, & Jawa, V. (2025). Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations. Nucleic Acids Research, 53(18). https://doi.org/10.1093/nar/gkaf778
Vancouver
Christensen JK, Colletti N, Hooshfar S, Jiang RR, Kuo C, Lindmark B, et al. Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations. Nucleic Acids Research. 2025;53(18). doi:10.1093/nar/gkaf778
BibTeX
@article{Christensen2025,
author = {Christensen, Jesper Kammersgaard and Colletti, Nicholas and Hooshfar, Shirin and Jiang, Rongrong Rosa and Kuo, Carol and Lindmark, Bosse and Lumen, Annie and Youssef, Amir S and Albertolle, Matthew and Aluri, Krishna C and Chen, Linzhi and Chen, Jingxian and Chopda, Girish and Chua, Xien Yu and Morais, Pedro and Dubois, Barent and Gibbons, Francis Frank and Gudey, Shyam Kumar and Gupta, Swati and Hood, Steve and Humphreys, Sara and Husser, Christophe and Huth, Felix and Jani, Darshana and Jian, Wenying and Kakuda, Thomas and Kurz, Jeffrey and Linnebjerg, Helle and Liu, Jing and Lohmann, Sabine and Niu, Tao and Root, Katharina and Singla, Sumeet and Tang, Chenxiao and Veluri, Ravikanth and Zhang, Guangnong Sunny and Zhang, Steven and Jawa, Vibha},
title = {Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {18},
doi = {10.1093/nar/gkaf778}
}
EUVIMED